This SPEKTRUM issue on the topic "Neurological Diseases" is overshadowed by the coronavirus crisis, a subject that currently preoccupies us all and dominates our lives. The disease COVID-19 stands for collective uncertainty, existential threat and fear, triggered by the absence of an effective treatment. Such a lack of therapies links the two themes of this issue, which has inevitably been affected by SARS-CoV-2.
This issue focuses on neurology, a field that combines excellent diagnostics with often unsatisfactory therapeutic options. Many diseases of the nervous system cannot be treated at all; in others, drug therapy — as in epilepsy, for example — is accompanied by side effects that can significantly impair life. The treatment of various forms of epilepsy, especially in children, is therefore also one of the rewarding tasks for homeopaths. In many cases seizure disorders are associated with developmental delays. Under homeopathic treatment developmental progress is then caught up, even when severe combined disorders of the central nervous system are present. Homeopathy achieves similarly good results in many cases of multiple sclerosis as it does with seizure disorders and developmental disorders. In addition, the international authors present case studies treating patients who suffer from stubborn neuralgias, severe sensory disturbances and neurodegenerative diseases. A contribution on the treatment of dementia, injuries and infections of the CNS with remedies from the group of fungi promises new insights.
The destructive nature and invasive global spread of fungi make them, for some homeopaths, candidates in the search for endemic remedies for COVID-19. We have closely observed this worldwide search in recent months, followed attentively the debate over differing understandings of a genius epidemicus, and collected colleagues' reports of experience and the results they have published. In doing so we concentrated on the authors who, through their joint work on this journal, are in regular exchange with us and who experienced the pandemic firsthand in epicentres such as Iran, Italy, Spain, Great Britain or New York in the first months.